Sorafenib in metastatic thyroid cancer

Capdevila, Jaume; Iglesias, Lara; Halperín, Irene; Segura, Ángel; Martínez‐Trufero, Javier; Vaz, María Ángeles; Corral, J.; Obiols, Gabriel; Grande, Enrique; Grau, Juan J.; Tabernero, Josep

doi:10.1530/erc-11-0351

Cited by 96 publications

(75 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Grade 4: myocardial infarction and small-cell lung cancer Capdevila et al (2012) Grade 3: HFS (20) been studied as well, mainly comprising rosiglitazone, vorinostat, thalidomide, celecoxib, and selumetinib (Mrozek et al 2006, Ain et al 2007, Kebebew et al 2009, Woyach et al 2009, Ho et al 2013. Though most of them exhibited modest efficacy, selumetinib, a MAPK kinase (MEK) 1 and MEK 2 inhibitor, increased the uptake of iodine-124 in 12 of the 20 patients (60%).…”

Section: Discussionmentioning

confidence: 99%

Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis

Shen¹,

Qiu²,

Luo³

2013

Endocrine-Related Cancer

View full text Add to dashboard Cite

The advent of biologically targeted agents and increased understanding of thyroid carcinogenesis have generated much interest in the development of biologically targeted therapeutic agents for thyroid cancer. Among them, sorafenib is the most commonly studied drug. The current meta-analysis was carried out to estimate the efficacy and safety of sorafenib administered in radioiodine-refractory differentiated thyroid cancer patients. An electronic search was conducted using PubMed/MEDLINE and EMBASE. Statistical analyses were carried out using either random-effects or fixed-effects models according to heterogeneity. All the statistical analyses were carried out using the Stata version 12.0 software. Seven eligible studies were identified. The final results indicated that 22% of the patients (95% CI: 15-28) achieved a partial response. Hand-foot syndrome, diarrhea, fatigue, rash, weight loss, and hypertension were the most frequently observed adverse effects (AEs) associated with sorafenib use and the incidence of these AEs (all grades) was 80% (95% CI: 68-91), 68% (95% CI: 59-77), 67% (95% CI: 57-78), 66% (95% CI: 50-82), 52%(95% CI: 33-72), and 31% (95% CI: 21-42) respectively. Sixty-two percent (95% CI: 36-89) patients required dose reductions due to toxicity of sorafenib. As far as PR and AEs are concerned, the results of this meta-analysis indicate that sorafenib has a modest effect in patients with radioiodine-refractory differentiated thyroid cancer and the high incidence of AEs associated with this agent may affect the quality of patients' lives. Though the use of sorafenib in the treatment of radioiodinerefractory differentiated thyroid cancer is considered promising by most physicians working in this field, more effective agents with less toxicity and cost are still needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis

Shen¹,

Qiu²,

Luo³

2013

Endocrine-Related Cancer

View full text Add to dashboard Cite

show abstract

“…These findings have suggested that sorafenib may significantly improve outcomes in patients with DTC. Several Phase II trials have assessed the effects of sorafenib monotherapy in over 200 patients with thyroid cancer, most with DTC, with other patients having medullary and anaplastic carcinomas (14)(15)(16)(17)(18)(19)(20). The median progression-free survival (PFS) ranged from 14 to 24 months, with PR rates as high as 38%, and disease control rates (defined as SD plus PR) of 59%-100%.…”

Section: Adverse Eventsmentioning

confidence: 99%

Response to sorafenib treatment in advanced metastatic thyroid cancer

Pitoia

2014

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

Objective: To investigate the efficacy of sorafenib in progressive radioiodine resistant metastatic thyroid carcinoma. Subjects and methods: Off-label observational study. Sorafenib 400 mg twice daily was evaluated. Therapy duration was 12 ± 3 months (range 6-16 months). Results: Eight patients were included (seven papillary, one insular variant). The eight patients meeting study criteria received sorafenib 400 mg orally twice a day until disease progression or unacceptable toxicity developed. One patient showed a partial response with tumor regression of -35%, six months after the beginning of the treatment; five patients exhibited stable disease and two patients had progressive disease and died. Thyroglobulin decreased within 4 weeks in all patients by 50% ± 23%. Adverse events: one patient had heart failure, and recovered after sorafenib withdrawal. However, she died five months later of sudden death. Conclusion: These data suggest a possible role for sorafenib in the treatment of progressive metastatic DTC. Adverse event are usually manageable, but severe ones may appear and these patients should be strictly controlled. Arq Bras Endocrinol Metab. 2014;58(1):37-41 Keywords Metastasis; sorafenib; thyroid; cancer RESUMO Objetivo: Investigar a eficácia do sorafenibe no carcinoma de tireoide metastático progressivo e refratário à iodoterapia. Sujeitos e métodos: Estudo observacional do efeito do sorafenibe off-label administrado 400 mg duas vezes ao dia. A duração da terapia foi de 12 ± 3 meses (variação de 6-16 meses). Resultados: Oito pacientes foram incluídos (sete com variante papilífera e um com variante insular). Os oito pacientes que preencheram os critérios do estudo receberam o sorafenibe 400 mg por via oral duas vezes por dia até progressão da doença ou toxicidade inaceitável. Um paciente apresentou uma resposta parcial com regressão tumoral da lesão alvo de 35% seis meses após o início do tratamento; cinco pacientes apresentaram doença estável e dois pacientes progrediram e morreram. A tireoglobulina diminuiu 50% ± 23% em 4 semanas em todos os pacientes. Eventos adversos: um paciente teve insuficiência cardíaca e morreu por morte súbita cinco meses após a retirada do sorafenibe. Conclusão: Esses dados sugerem um possível papel para sorafenibe para o tratamento do CDT metastático progressivo. Arq Bras Endocrinol Metab. 2014;58(1):37-41Descritores

show abstract

“…Sorafenib in the form of oral tablets was permitted by the U.S. Food and Drug Administration (FDA) for use in the treatment of late-stage metastatic DTC in 2013. The effectiveness of sorafenib in DTC differs depending on the trial, and partial response (PR) rate ranges from 6% to 49% [62]. In a recent large trial progressive-free survival (PFS) reached 10.8% in I-131-resistant DTCs (compared to PFS 5.8% in a placebo group) [63].…”

Section: Szkolenie Podyplomowementioning

confidence: 99%

Rak pęcherzykowy tarczycy z przerzutami do wątroby — diagnostyka, leczenie i prognoza

Kałużna

Gołąb

Czepczyński

et al. 2015

Endokrynologia Polska

View full text Add to dashboard Cite

Follicular thyroid carcinoma (FTC) is the second most common type of thyroid cancer (TC) and accounts for approximately 10% of all TC cases. Liver metastases are a rare presentation in 0.5-1% of follicular thyroid cancers, usually occurring in the setting of widely disseminated FTC disease, and their presence is associated with poor prognosis. Until now, there have been only 30 cases of FTC liver metastases described in the literature. Herein, we review publications and describe diagnostic tools that may be used in the diagnosis and follow-up of FTC metastases to the liver, including biopsy and imaging techniques like US, CT, MRI, SPECT, PET, and radioiodine scintigraphy. We also present and discuss current methods of treatment, e.g. TSH suppressive therapy with levothyroxine, surgery, radiofrequency ablation (RFA), transarterial embolisation (TAE), liver transarterial chemoembolisation (TACE), chemotherapy with cisplatin and doxorubicin, treatment with Indium-111-octreotide (or its analogues), and tyrosine kinase inhibitors (sorafenib, sunitinib). At the end we describe the course, results of diagnostics, and treatment in a patient with large multiple FTC metastases to the liver. Key words: differentiated thyroid carcinoma (DTC); follicular thyroid cancer (FTC); liver metastases; positron emission tomography (PET); whole body scintigraphy (WBS) StreszczenieRak pęcherzykowy tarczycy (FTC) jest drugim najczęstszym typem raka tarczycy (TC) i stanowi około 10% wszystkich TC. Przerzuty do wątroby występują w 0,5-1% przypadków FTC, zwykle w przypadku znacznie zaawansowanej choroby nowotworowej i wiążą się ze złą prognozą. Do tej pory, tylko 30 przypadków FTC z przerzutami do wątroby zostało opisanych w literaturze. W niniejszej pracy dokonano przeglądu literatury i opisu metod diagnostycznych jakie mogą być użyte w badaniu i kontroli przerzutów FTC do wątroby, w tym biopsji, technik obrazowych, takich jak: USG, KT, MRI, SPECT, PET i scyntygrafii jodowej. Zaprezentowano i omówiono aktualne metody leczenia: terapię L-tyroksyną w dawce supresyjnej, leczenie operacyjne, ablację prądem o częstotliwości fal radiowych (RFA), embolizację przeztętniczą (TAE), przeztętniczą chemoembolizację, chemioterapię z użyciem cisplatyny i doksyrubicyny, leczenie z użyciem analogów somatostatyny w tym octreotydu znakowanego izotopem indu 111In, czy terapię z użyciem inhibitorów kinazy tyrozynowej (sorafenib, sunitynib). Na końcu opisano przebieg choroby, wyniki badań diagnostycznych i podjęte leczenie u chorej z ogromnymi mnogimi przerzutami FTC do wątroby. (Endokrynol Pol 2016; 67 (3): 332-347) Słowa kluczowe: zróżnicowany rak tarczycy; rak pęcherzykowy tarczycy; przerzuty do wątroby; pozytronowa tomografia emisyjna (PET); scyntygrafia całego ciała

show abstract

Sorafenib in metastatic thyroid cancer

Cited by 96 publications

References 22 publications

Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis

Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis

Response to sorafenib treatment in advanced metastatic thyroid cancer

Rak pęcherzykowy tarczycy z przerzutami do wątroby — diagnostyka, leczenie i prognoza

Contact Info

Product

Resources

About